1.
In high-CV-risk patients without diabetes, an SBP target < 120 vs < 140 reduced major CV events and all-cause mortality
2.
In high-risk type 2 diabetes, an SBP target of < 120 vs < 140 did not reduce major CV events (although stroke was reduced)
3.
Lowering DBP (≤80 vs ≤85 vs ≤90) did not improve CV outcomes overall; diabetics had fewer major CV events with lower BP goals
4.
Chlorthalidone was similar to amlodipine or lisinopril for CHD death/nonfatal MI, but had less HF (vs amlodipine) and less stroke/combined CVD (vs lisinopril)—supporting thiazides as first-line
5.
Amlodipine±perindopril strategy vs atenolol+thiazide lowered all-cause/CV mortality, CV events/procedures, stroke; at 16-year follow-up the amlodipine-based arm had a reduction in stroke
6.
Benazepril–amlodipine was superior to benazepril–hydrochlorothiazide in reducing CV events in patients with high-risk HTN
7.
In hypertensive patients with ECG-defined LVH, a losartan vs atenolol achieved similar BP reduction, but losartan reduced CV death/MI/stroke — mainly by fewer strokes — with less new-onset diabetes
8.
In African American patients with mild-to-moderate CKD, ramipril slowed the decline in GFR more effectively than metoprolol or amlodipine; intensive vs standard BP targets did not clearly add renal benefit
9.
In older adults (60+) with isolated systolic hypertension, antihypertensive treatment (chlorthalidone-based) reduced stroke and major cardiovascular events compared with placebo
10.
Treating adults ≥80 years with indapamide SR ± perindopril to a target 150/80 reduced stroke, HF, and all-cause mortality, with fewer serious adverse events
11.
In DM + HTN, tight BP control (<150/85) using an ACE inhibitor or β-blocker reduced DM-related endpoints (micro- and macrovascular complications) and lowered DM-related mortality compared with less-tight control (target <180/105 mmHg)
12.
Adding routine fixed-dose perindopril–indapamide to usual care in DM modestly lowered BP and reduced major vascular events (macro+microvascular composite) and lowered all-cause and CV mortality versus placebo
13.
In high-risk DM + HTN, SBP target <120 vs <140 reduced major CV events with similar serious adverse events overall but more symptomatic hypotension and hyperkalemia
